TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Stockholders Equity Over TimeContracting
Percentile Rank50
3Y CAGR+7.4%
Studio
Year-over-Year Change

Net worth of the company (assets minus liabilities)

3Y CAGR
+7.4%/yr
Annual compound
Percentile
P50
Within normal range
vs 3Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$123.12M-48.9%
2024$240.97M+59.7%
2023$150.87M+51.7%
2022$99.43M-38.2%
2021$160.78M+478.6%
2020$-42.46M-199.8%
2019$42.54M-